• News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Digital edition
    • Archived issues
    • Media kit
    • Submit Press Release
  • White Papers
  • Events
  • Suppliers
  • E-Alert
  • Contact us
  • FREE newsletter subscription
  • Search
  • Menu Menu
International Hospital
  • AI
  • Cardiology
  • Oncology
  • Neurology
  • Genetics
  • Orthopaedics
  • Research
  • Surgery
  • Innovation
  • Medical Imaging
  • MedTech
  • Obs-Gyn
  • Paediatrics

Archive for category: E-News

E-News

Duration of RBC storage does not affect short-term pulmonary, immunologic, or coagulation status

, 26 August 2020/in E-News /by 3wmedia

There is no difference in early measures of pulmonary function, immunologic status or coagulation status after fresh versus standard issue single-unit red blood cell (RBC) transfusion, according to a new study from the Mayo Clinic.

‘Longer duration of RBC storage is thought to increase the risk of transfusion-related pulmonary complications,’ said Daryl J. Kor, assistant professor of anaesthesiology at the Mayo Clinic College of Medicine. ‘In our study of 100 intubated, mechanically ventilated patients, we did not see evidence for an increased risk associated with RBC storage duration, at least not in the early post-transfusion period.’

In the double-blind trial, 50 patients were randomised to receive fresh (median storage duration = 4.0 days) RBC and 50 were randomised to receive standard issue RBC (median storage duration = 26.5 days). The primary outcome measure was change in pulmonary gas exchange, as measured by the partial pressure of arterial oxygen to fraction of inspired oxygen concentration ratio (ΔPaO2/FiO2). Post-transfusion measurements were performed upon completion of the transfusion and within two hours of the transfusion (median 1.9 hours in the fresh RBC group and 1.8 hours in the standard issue RBC group).

No significant differences between groups were seen in the primary outcome measure of change in PaO2/FiO2 ratio (2.5 +/- 49.3 vs. -9.0 +/- 69.8; fresh RBC vs. standard issue RBC; p = 0.22). Similarly, no significant differences were seen for any of the other outcome measures of pulmonary function (fraction of dead space ventilation, dynamic and static pulmonary compliance), immunologic status (tumor necrosis factor-alpha, interleukin-8, C-reactive protein) or coagulation status (fibrinogen, anti-thrombin consumption).

‘Our data do not support a significant effect of RBC storage duration on respiratory, immunologic or coagulation parameters in the immediate post-transfusion period,’ said Dr. Kor. ‘Previous observational studies linking RBC storage duration and respiratory complications may have suffered from bias and unmeasured confounding, which were more effectively addressed in our double-blind, randomised trial study design.’

The study did have some limitations, including the short duration of follow-up, the study’s limited sample size and the single centre, tertiary-care setting, which may limit the generalisability of the results.

‘Given the lack of an association between RBC storage duration and evidence of transfusion-related pulmonary complications in our study, randomization to fresh versus longer storage duration RBC in clinical trials would clearly seem ethical,’ said Dr. Kor. ‘Further study will need to clarify the impact of RBC storage duration on other patient-centered outcomes.’

EurekAlert
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:42:452020-08-26 14:43:05Duration of RBC storage does not affect short-term pulmonary, immunologic, or coagulation status

First electronic retinas implanted in the UK

, 26 August 2020/in E-News /by 3wmedia

Surgeons in Oxford are the first in the UK to successfully implant an electronic retina into the back of an eye.
On 22 March 2012, Chris James became the first patient in the UK to receive this ground-breaking surgery as part of a clinical trial being carried out at John Radcliffe Hospital and King’s College Hospital in London.
Mr James’s operation took place at the Oxford Eye Hospital with the surgical team led by Professor Robert MacLaren.
He was assisted by Mr Tim Jackson, a consultant ophthalmic surgeon at King’s College Hospital in London.
The following week, a second patient, Robin Millar, a 60 year old music producer from London, received a retinal implant at King’s College Hospital, with Professor MacLaren assisting Mr Jackson.
Both patients were able to detect light immediately after the electronic retinas were switched on, and are now beginning to experience some restoration of useful vision. Further operations are now planned for other suitable patients.
The retinal implants have been developed by Retina Implant of Germany to restore some sight to people with retinitis pigmentosa, an inherited condition that affects around one in every 3,000 – 4,000 people in Europe.
Retinitis pigmentosa is a progressive disease that sees light-detecting cells in the retina deteriorate over time.
Retina Implant’s devices are designed to replace the lost cells in the retina. Patients have a small microchip containing 1,500 tiny electronic light detectors implanted below the retina. The optic nerve is able to pick up electronic signals from the microchip and patients can begin to regain some sight once more.
Professor MacLaren explains: ‘What makes this unique is that all functions of the retina are integrated into the chip. It has 1,500 light sensing diodes and small electrodes that stimulate the overlying nerves to create a pixellated image. Apart from a hearing aid-like device behind the ear, you would not know a patient had one implanted.’
Chris James, 54, a council worker from Wiltshire, first began to experience night blindness in his mid-20s and was diagnosed with retinitis pigmentosa following a referral to Oxford Eye Hospital.
For a number of years, Chris’ vision remained relatively stable. But in 1990, a large dip in his vision left him legally blind. In 2003, another decrease in vision rendered Chris completely blind in his left eye and only able to distinguish lights in his right.
After having the artificial retina implanted in his left eye, Chris can now recognise a plate on a table and other basic shapes. And his vision is continuing to improve as he learns to use the electronic chip in an eye that has been completely blind for over a decade.
The operation took eight hours and first required implantation of the power supply which is buried under the skin behind the ear, similar to a cochlear implant. This part of the operation was performed by Mr James Ramsden of Oxford University Hospitals assisted by Mr Markus Groppe, an academic clinical lecturer at the University of Oxford.
The electronic retina was then inserted into the back of the eye and stitched into position before being connected to the power supply.
Three weeks after the operation, Chris’ electronic retina was switched on for the first time. After some initial tuning and testing, Chris was able to distinguish light against a black background.
‘As soon as I had this flash in my eye, this confirmed that my optic nerves are functioning properly which is a really promising sign,’ Chris said. ‘It was like someone taking a photo with a flashbulb, a pulsating light, I recognised it instantly.’
Chris continues to have monthly follow-up testing of his microchip. In the meantime, he is testing the microchip at home. ‘It’s obviously early days but it’s encouraging that I am already able to detect light where previously this would have not been possible for me. I’m still getting used to the feedback the chip provides and it will take some time to make sense of this. Most of all, I’m really excited to be part of this research.’
Oxford Eye Hospital

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:42:452020-08-26 14:42:52First electronic retinas implanted in the UK

Second study investigates two-arm blood pressure difference

, 26 August 2020/in E-News /by 3wmedia

44 per cent of patients being treated for high blood pressure and who took part in the study either suffered vascular disease or died over a 10-year period
In January a research team from the Peninsula College of Medicine and Dentistry reported the first systematic review of findings related to the risk factors associated with a difference in blood pressure between arms.
The first study, which was published in The Lancet, suggested that a difference of more than 10mmHg or 15mmHg in systolic blood pressure (the

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:42:452020-08-26 14:43:00Second study investigates two-arm blood pressure difference

Drug side-effects are so bad women end treatment and risk return of cancer

, 26 August 2020/in E-News /by 3wmedia

Why do so many postmenopausal women who are treated for oestrogen-sensitive breast cancer stop using aromatase inhibitors that help prevent the disease from recurring? The first study to actually ask the women themselves, as well as the largest, most scientifically rigorous study to examine the question, carried out at Northwestern University, USA reports that 36 percent of women stop treatment early because of the medications

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:42:452020-08-26 14:43:08Drug side-effects are so bad women end treatment and risk return of cancer

UH students develop prototype device that translates sign language

, 26 August 2020/in E-News /by 3wmedia

Too often, communication barriers exist between those who can hear and those who cannot. Sign language has helped bridge such gaps, but many people are still not fluent in its motions and hand shapes.
Thanks to a group of University of Houston students, the hearing impaired may soon have an easier time communicating with those who do not understand sign language. During the past semester, students in UH

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:42:452020-08-26 14:42:47UH students develop prototype device that translates sign language

Varian Medical Systems and Siemens Healthcare to collaborate in radiotherapy and radiosurgery

, 26 August 2020/in E-News /by 3wmedia

Varian Medical Systems and Siemens Healthcare announce global collaboration to advance clinical capabilities and offerings in radiotherapy and radiosurgery.

Varian Medical Systems and Siemens Healthcare have announced the signing of a strategic global partnership to provide advanced diagnostic and therapeutic solutions and services for treating cancer with image-guided radiotherapy and radiosurgery. The collaboration covers the mutual marketing and representation of products for imaging and treatment in the global radiation oncology business. This collaboration further comprises the development of software interfaces between Siemens and Varian treatment systems. The two companies will also investigate opportunities for joint development of new products for image-guided radiotherapy and radiosurgery.

Under the agreement that was signed this week, Varian will represent Siemens diagnostic imaging products such as CT, PET/CT or MRI to radiation oncology clinics around the world beginning immediately in most international markets and expanding to North America later this year. Siemens Healthcare will similarly represent Varian equipment and software for radiotherapy and radiosurgery within its offerings to its healthcare customers. This will enable the companies to offer comprehensive solutions to support the entire clinical workflow from imaging to treatment. Siemens will continue to service and support its global installed base of approximately 2,000 medical linear accelerators. The agreement will give Siemens customers more choices for therapy equipment, including smooth transition and interface to Varian equipment, as aging accelerators are due for replacement.

Furthermore, Varian and Siemens will develop interfaces that will enable connecting Varian

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:42:452020-08-26 14:42:55Varian Medical Systems and Siemens Healthcare to collaborate in radiotherapy and radiosurgery

France implants: PIP boss Mas jailed for bail default

, 26 August 2020/in E-News /by 3wmedia

The founder of the French breast implant company at the heart of a global health scare has been jailed after failing to pay his bail. Jean-Claude Mas, 72, was released on 100,000 euro (

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:42:452020-08-26 14:43:02France implants: PIP boss Mas jailed for bail default

A non-invasive intracellular ‘thermometer’ with fluorescent proteins has been created

, 26 August 2020/in E-News /by 3wmedia

A team from the Institute of Photonic Sciences (ICFO) has developed a technique to measure internal cell temperatures without altering their metabolism. This finding could be useful when distinguishing healthy cells from cancerous ones, as well as learning more about cellular processes.
Temperature controls many of the cell’s life processes, such as splitting and metabolism. A European research team led by the Institute of Photonic Sciences (ICFO), which has the Severo Ochoa mark of excellence, has published a non-invasive method that offers quicker, more precise data from measuring intracellular heat from green fluorescent proteins (GFP).
‘A unique characteristic of our method is that it does not alter any cellular process’ Romain Quidant, ICFO researcher and study co-ordinator, explains to SINC. Unlike other techniques, this method does not stress or alter the behaviour of the cell as it does not need to be inserted into any molecules or any other synthetic nano-object that is sensitive to the internal temperature.
One of the most promising outcomes is a better understanding of cellular processes, such as those involved in metastasis. Furthermore, the possibility of obtaining information about intracellular temperature could be used to ‘differentiate normal cells from cancerous ones in a quick, non-invasive manner’ Sebastian Thompson Parga, ICFO researcher and co-author of the project.
From intracellular temperature, we can deduce how the energy used by the body in the uncontrolled spreading of cancer cells flows.
In this interdisciplinary study, biology uses physical measurements of energy transmission to study processes such as gene expression, metabolism and cell splitting.
The technique used is known by the name of ‘fluorescence polarisation anisotropy’ (FPA) as it allows the difference in polarisation between light that fluorescent molecules receive, and that which they emit later, to be measured. In the words of Quidant, ‘this difference in polarisation (anisotropy) is directly connected to the rotating of the GFP molecules and therefore with temperature’.
The authors of the study ensure that biologists will be able to implement this technique in experimental set-ups and obtain the cell temperature as another observable detail. In 2008, when Osamu Shimomura, Martin Chalfie and Roger Y. Tsien won the Nobel Chemistry Prize for discovering and developing GFP, they resolved many complications in biomedical research. EurekAlert

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:42:452020-08-26 14:42:49A non-invasive intracellular ‘thermometer’ with fluorescent proteins has been created

Predictors identified for re-hospitalisation among post-acute stroke patients

, 26 August 2020/in E-News /by 3wmedia

Stroke patients receiving in-patient rehabilitation are more likely to land back in the hospital within three months if they are functioning poorly, show signs of depression and lack social support according to researchers at the University of Texas Medical Branch (UTMB) at Galveston. Hospital readmission for older adults within 30 days of discharge costs Medicare roughly $18 billion annually.
Among the first of such research to explore the risk of re-hospitalisation among this patient segment, the study is available online at The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. The findings are timely as effective this October hospitals will be held accountable for high short-turnaround readmission rates.
According to Dr. Kenneth Ottenbacher, Director, Center for Rehabilitation Sciences, and Associate Director, UTMB Sealy Center on Ageing, ‘by identifying clear demographic, clinical and environmental factors that lead to re-hospitalisation, we can develop meaningful quality indicators for post-acute care that target ways to improve patients’ health and contain costs by reducing the likelihood of readmission.’
Currently, more than 30 percent of stroke patients receive in-patient rehabilitation after release from acute care, he said.
‘Though we intuitively know that these patients are at highest risk for being re-hospitalised

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:42:452020-08-26 14:42:58Predictors identified for re-hospitalisation among post-acute stroke patients

T-rays technology could help develop Star Trek-style hand-held medical scanners

, 26 August 2020/in E-News /by 3wmedia

Scientists have developed a new way to create electromagnetic Terahertz (THz) waves or T-rays – the technology behind full-body security scanners. The researchers behind the study say their new stronger and more efficient continuous wave T-rays could be used to make better medical scanning gadgets and may one day lead to innovations similar to the ‘tricorder’ scanner used in Star Trek.
In the study, researchers from the Institute of Materials Research and Engineering (IMRE), a research institute of the Agency for Science, Technology and Research (A*STAR) in Singapore, and Imperial College London in the UK have made T-rays into a much stronger directional beam than was previously thought possible, and have done so at room-temperature conditions. This is a breakthrough that should allow future T-ray systems to be smaller, more portable, easier to operate, and much cheaper than current devices.
The scientists say that the T-ray scanner and detector could provide part of the functionality of a Star Trek-like medical ‘tricorder’ – a portable sensing, computing and data communications device – since the waves are capable of detecting biological phenomena such as increased blood flow around tumorous growths. Future scanners could also perform fast wireless data communication to transfer a high volume of information on the measurements it makes.
T-rays are waves in the far infrared part of the electromagnetic spectrum that have a wavelength hundreds of times longer than those that make up visible light. Such waves are already in use in airport security scanners, prototype medical scanning devices and in spectroscopy systems for materials analysis. T-rays can sense molecules such as those present in cancerous tumours and living DNA, since every molecule has its unique signature in the THz range. They can also be used to detect explosives or drugs, for gas pollution monitoring or non-destructive testing of semiconductor integrated circuit chips.
Current T-ray imaging devices are very expensive and operate at only a low output power, since creating the waves consumes large amounts of energy and needs to take place at very low temperatures.
In the new technique, the researchers demonstrated that it is possible to produce a strong beam of T-rays by shining light of differing wavelengths on a pair of electrodes – two pointed strips of metal separated by a 100 nanometre gap on top of a semiconductor wafer. The structure of the tip-to-tip nano-sized gap electrode greatly enhances the THz field and acts like a nano-antenna to amplify the wave generated. In this method, THz waves are produced by an interaction between the electromagnetic waves of the light pulses and a powerful current passing between the semiconductor electrodes. The scientists are able to tune the wavelength of the T-rays to create a beam that is useable in the scanning technology.
Lead author Dr Jing Hua Teng, from A*STAR

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:42:452020-08-26 14:43:05T-rays technology could help develop Star Trek-style hand-held medical scanners
Page 60 of 236«‹5859606162›»

Latest issue of International Hospital

April 2024

13 October 2025

Global mortality rates fall sharply, but youth deaths surge in stark health divide

9 October 2025

electronRx launches pDx app for remote lung monitoring

9 October 2025

Hospital teams reduce unnecessary preoperative testing by tailoring strategies to local workflows

Digital edition
All articles Archived issues

Free subscription

View more product news

Get our e-alert

The medical devices information portal connecting healthcare professionals to global vendors

Sign in for our newsletter
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Archived issues
    • Media kit
    • Submit Press Release

Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@interhospi.com

PanGlobal Media IS not responsible for any error or omission that might occur in the electronic display of product or company data.

Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlyCookie settings

Cookie and Privacy Settings



How we use cookies

We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.

Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.

We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.

We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.

.

Google Analytics Cookies

These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.

If you do not want us to track your visit to our site, you can disable this in your browser here:

.

Other external services

We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page

Google Webfont Settings:

Google Maps Settings:

Google reCaptcha settings:

Vimeo and Youtube videos embedding:

.

Privacy Beleid

U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.

Privacy policy
Accept settingsHide notification only

Sign in for our newsletter

Free subscription